Mometasone furoate is under clinical development by EsoCap and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mometasone furoate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mometasone furoate overview
Mometasone furoate (ESO-101) is under development for the treatment of eosinophilic esophagitis. The drug candidate is a topical corticosteroid. It is administered through oral route.
EsoCap is a company that improve the lives of patients affected by esophageal diseases. The company is headquartered in Basel, Basel-Stadt, Switzerland.
For a complete picture of Mometasone furoate’s drug-specific PTSR and LoA scores, buy the report here.